Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH‐binding inhibitor immunoglobulin
- 1 February 1994
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 40 (2), 215-219
- https://doi.org/10.1111/j.1365-2265.1994.tb02471.x
Abstract
TSH-binding inhibitory immunoglobulin (TBII) is undetectable in about 10% of untreated Graves' disease patients, but the clinical characteristics and immunological significance of this finding are unknown. In this study we evaluated the clinical characteristics of TBII negative Graves' disease. We examined TBII in 1048 untreated patients at Kuma hospital from 1986 to 1990 and found 69 TBII undetectable patients (12 men and 57 women, mean age +/- SEM 35 +/- 2 years, group A). We compared the clinical characteristics and immunological findings of group A with 57 untreated TBII detectable Graves' patients who were selected randomly (11 men and 46 women, mean age +/- SEM 40 +/- 2 years, group B). T4, TSH, FT4, FT3, 123I thyroid uptake, TBII, thyroid stimulating antibodies (TSAb) and the volume of the thyroid using ultrasonography were measured at the first visit. Serum T4, FT4 and FT3 levels in group A were significantly lower than those in group B (P < 0.001). The values of TSAb in group A were significantly lower than those in group B (593 +/- 67 (mean +/- SE) vs 2143 +/- 280%, respectively, P < 0.001). The 123I thyroid uptake in group A was significantly lower than that in group B (53.1 +/- 1.1 vs 61.4 +/- 1.4%, respectively, P < 0.01). The thyroid volume in group A was significantly smaller than that in group B (39.1 +/- 3.0 vs 51.3 +/- 3.3 ml, respectively, P < 0.01). TSAb was undetectable in about 10% (6) of the TBII negative untreated Graves' patients at their first visit. In the present study, untreated TBII negative patients with Graves' disease were characterized by mild elevation of thyroid hormones, mildly elevated 123I uptake, weak TSAb activities and small goitres. The finding of both TBII and TSAb negative titres in untreated Graves' disease patients was also confirmed.Keywords
This publication has 23 references indexed in Scilit:
- Thyroid stimulatory autoantibodies in different patients with autoimmune thyroid disease do not all recognize the same components of the human thyrotropin receptor: selective role of receptor amino acids Ser25-Glu30Journal of Clinical Endocrinology & Metabolism, 1992
- Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors.JCI Insight, 1991
- Optimization and Clinical Assessment of a Radioreceptor Assay for Thyrotropin-Binding Inhibitor ImmunoglobulinsEndocrinologia Japonica, 1987
- TSH RECEPTOR ANTIBODY SYNTHESIS BY THYROID LYMPHOCYTESClinical Endocrinology, 1986
- EVIDENCE THAT THYROID-STIMULATING ANTIBODY IS PRODUCED IN THE THYROID GLANDThe Lancet, 1984
- AN IMPROVED RADIORECEPTOR ASSAY FOR TSH RECEPTOR ANTIBODIESClinical Endocrinology, 1982
- Thyroid Gland Volume Estimated by Use of Ultrasound In Addition to ScintigraphyActa Radiologica: Oncology, Radiation, Physics, Biology, 1978
- RELATION OF THYROID-STIMULATING IMMUNOGLOBULINS TO THYROID FUNCTION AND EFFECTS OF SURGERY, RADIOIODINE, AND ANTITHYROID DRUGSThe Lancet, 1975
- THYROID-STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASEThe Lancet, 1974